Genomic Alterations in Porokeratosis Pathogenesis

Porokeratosis encompasses a group of keratinisation disorders defined by distinctive cornoid lamellae and driven predominantly by disruptions in the mevalonate (isoprenoid) biosynthesis pathway. Germline mutations in key enzymes—mevalonate kinase (MVK), phosphomevalonate kinase (PMVK), mevalonate diphosphate decarboxylase (MVD) and farnesyl diphosphate synthase (FDPS)—have been shown to underlie familial and sporadic forms. Loss or reduction of wild-type allele expression in lesional keratinocytes, often via allelic expression imbalance or gene conversion, exacerbates metabolic bottlenecks, precipitating corneocyte apoptosis and defective differentiation. Somatic second-hit events contribute to mosaic and linear presentations, correlating with clinical severity and age of onset. Integrating mutational spectra with imaging and metabolomic profiles has refined disease classification and highlighted potential for pathway-targeted therapies, such as topical statin-cholesterol formulations. Genetic testing now informs prognosis and guides surveillance for malignant transformation, underscoring global relevance in dermatogenetics and personalised medicine.

Research from Nature Portfolio

Recent studies have elucidated the role of PMVK loss-of-function variants in disseminated superficial porokeratosis. A truncating mutation in the PMVK gene was shown to disrupt enzyme localisation, solubility and expression in keratinocyte models, leading to increased apoptosis beneath cornoid lamellae and incomplete terminal differentiation. Co-segregation analyses in extended pedigrees established autosomal dominant inheritance, while functional assays in human epidermal cells demonstrated a direct link between PMVK deficiency and lesion formation. These findings reinforce the centrality of mevalonate pathway integrity in porokeratosis pathogenesis and pave the way for metabolic correction strategies.

Genomic Alterations in Porokeratosis Pathogenesis publication trend

The graph below shows the total number of articles in genomic alterations in porokeratosis pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

Cornoid lamella: A column of parakeratotic cells forming the histopathological hallmark of porokeratosis, marking focal keratinisation defects.

Mevalonate pathway: A metabolic cascade responsible for cholesterol and isoprenoid synthesis, central to membrane integrity and protein prenylation in keratinocytes.

Allelic expression imbalance: A disparity in transcriptional output between two alleles of a gene, often due to somatic alterations, leading to reduced functional protein levels.

Somatic mosaicism: The presence of genetically distinct cell populations within an individual arising from post-zygotic mutations, contributing to segmental or linear disease patterns.

References

1. Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants. Metabolites (2023).
2. Genomic variations of the mevalonate pathway in porokeratosis. eLife (2015).
3. Loss-of-function Mutation in PMVK Causes Autosomal Dominant Disseminated Superficial Porokeratosis. Scientific Reports (2016).